Borrás-BlascoJRamírez-HerráizENavarro-RuizA.Integration of persistence in the 5P-medicine approach for age-related chronic diseases. Int J Qual Health Care. 2024;36(2):mzae026. doi:10.1093/intqhc/mzae026
2.
Rodriguez GoicoecheaMTejedorTejada EBorrás BlascoJ. Persistence, current state of the art. Farm Hosp. 2024;48:141. doi:10.1016/j.farma.2023.07.015
3.
MegeedAMagasHAccursiMBurantCJHansenE.The impact of a pharmacist-led oral anticancer clinic on medication adherence and laboratory monitoring. J Oncol Pharm Pract. 2023;29(8):1921-1927. doi:10.1177/10781552231159870
4.
Borrás-BlascoJCornejoSValcuende-RosiqueA, et al. Persistence after switching from adalimumab biosimilar MSB11022 to adalimumab biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases. J Pharm Technol. 2024;40(2):123-130.
5.
Borrás-BlascoJCornejoSValcuende-RosiqueA, et al. Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis. Farm Hosp. 2025;49(1):45-52.
6.
Borrás-BlascoJAlcalaRValcuende-RosiqueACornejoS.Long-term real-world persistence of guselkumab in patients with moderate-to-severe psoriasis. Actas Dermosifiliogr. in press.
7.
BoguszMSucalaMApplebaumH, et al. Variants and determinants of unintentional and intentional medication nonadherence: a systematic review. Patient Prefer Adherence. 2024;18:1121-1136. doi:10.2147/PPA.S432100
8.
PinaMFDonatoJCabralACLopesF.Treatment persistence and switching patterns of biologics in patients with psoriatic arthritis: a real-world analysis. Clin Rheumatol. 2023;42(4):1237-1245. doi:10.1007/s10067-022-06446-w
9.
FeldmanSRBohnRLGaoR, et al. Poor adherence to and persistence with biologics in generalized pustular psoriasis: a claims based study using real‑world data from two large US databases. JAAD Int. 2024;15:78-83. doi:10.1016/j.jdin.2023.12.008
